top of page
Search

ClearSky at MDS 2025 | AI & Digital Biomarkers in Neurology

  • Alex Lou
  • Oct 20
  • 3 min read

ClearSky at MDS 2025: Advancing AI and Digital Biomarkers for Movement Disorder Research 

ree

ClearSky Medical Diagnostics had the privilege of participating in the 2025 International Congress of Parkinson’s Disease & Movement Disorders (MDS) in Honolulu, Hawaii (October 5–9). This marked our eighth year exhibiting at MDS, reflecting ClearSky’s long-standing commitment to advancing analytics and AI-driven insights in movement disorder research.

The MDS Congress is the world’s leading forum where clinicians, researchers, and industry innovators exchange progress and ideas across all areas of Parkinson’s disease, essential tremor, dystonia, and related movement disorders.


Conversations That Spiked at ClearSky’s Booth 

High Demand for AI Analytics in Clinical Research

Clinicians, academic researchers, and trial sponsors expressed strong interest in objective data analysis and digital endpoint quantification for movement disorder studies.ClearSky’s AI-driven analytics address these needs by transforming raw motion signals into validated, measurable biomarkers that support clinical interpretation and decision-making.

Industry Interest in Digital Biomarker Development

Pharma and MedTech partners were keen to explore how AI and data analytics can enhance drug development, device validation, and precision neurology.

With a proven record of developing and commercialising its own digital health solutions, ClearSky brings practical, hands-on experience, combining machine learning, signal processing, and statistical modelling to deliver implementation-ready insights that accelerate innovation in R&D.


Trust and Transparency

Across all audiences, one theme stood out — credibility.

Attendees valued ClearSky’s focus on transparent, validated, and reproducible AI methods, ensuring that digital tools stand up to clinical and regulatory scrutiny.


What Sets ClearSky Apart

Domain-Focused AI Expertise

Our team combines deep experience in neurology, motion analysis, and machine learning, enabling us to interpret complex signals — from tremor and bradykinesia to gait — with genuine clinical relevance.

AI Beyond Traditional Statistics

Traditional statistical approaches often rely on predefined hypotheses and linear relationships. In contrast, ClearSky’s AI-driven methods can efficiently uncover correlations and multidimensional patterns hidden within complex movement data — insights that might otherwise remain invisible.

This approach enables faster hypothesis generation, deeper understanding of disease mechanisms, and more sensitive identification of digital biomarkers.

Partnership-Driven Approach

ClearSky collaborates closely with clinicians, CROs, and industry teams, embedding our expertise to strengthen their capabilities in data analysis, trial design, and clinical interpretation.

Scientific Rigor

Our work is built on reproducibility and transparency — using explainable models, robust cross-validation, and clinical context to ensure each output can inform decision-making confidently.


How We Help Clinicians and Industry Move Forward

Whether you are leading Parkinson’s disease research, planning a movement-based clinical trial, or developing digital health solutions, ClearSky can support you with:

  • Expert consultation in applied AI – from study design to implementation, ensuring analytic methods align with research goals.

  • Digital data acquisition and validation – end-to-end support for collecting, standardizing, and validating motion, sensor, and digital biomarker data with clinical precision.

  • Multi-modal data integration and fusion – combining diverse data streams (wearable, video, clinical) to uncover complex correlations and relationships.

  • AI-powered data interpretation – translating complex signals into objective, actionable clinical insights that inform decisions and study outcomes.

  • Custom algorithm development – designing and training machine-learning models tailored to your dataset, disease domain, or endpoint needs.


Looking Ahead

Following MDS 2025, ClearSky is expanding collaborations and preparing case studies demonstrating AI’s role in quantifying movement disorder symptoms and predicting treatment response.

We’ll continue working closely with clinical and industry teams to apply our AI expertise where it can deliver the greatest impact — turning complex data into actionable insight.

If you visited our booth or are exploring ways to integrate AI into your research or development programs, we’d love to continue the conversation.


About ClearSky Medical Diagnostics

ClearSky Medical Diagnostics applies AI and Machine Learning to extract clinically meaningful insights from complex biomedical and movement data, supporting neurology research, clinical practice, and industry innovation worldwide.

By harnessing advanced AI techniques, ClearSky can uncover patterns and correlations that traditional statistical methods often find difficult to capture, enabling a deeper understanding of disease mechanisms and more precise, data-driven decision-making.

 
 
 

Comments

bottom of page